Irritable Bowel Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Irritable Bowel Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects the large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant, and antibiotic medications.
The Irritable Bowel Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Irritable Bowel Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 52 molecules, with 50 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Irritable Bowel Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Irritable Bowel Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Irritable Bowel Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAssembly Biosciences Inc
Bausch Health Companies Inc
Bilayer Therapeutics Inc
Biomica Ltd
Blue Therapeutics Inc
Boston Pharmaceuticals Inc
CB2 Therapeutics Inc
CinRx Pharma LLC
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co Ltd
Exeliom Biosciences SAS
exRNA Therapeutics Ltd
GEXVal Inc
Guangzhou Zhiyi Biotechnology Co Ltd
Healis Therapeutics LLC
ImmuneBiotech AB
Immunic Inc
Incannex Healthcare Ltd
Ironwood Pharmaceuticals Inc
ISOThrive Inc
KoBioLabs Inc
Malachite Innovations Inc
Max Delbruck Center for Molecular Medicine
MD Healthcare Inc
MGC Pharmaceuticals Ltd
Napo Pharmaceuticals Inc
Neurocrine Biosciences Inc
Nexpharm Korea Co Ltd
Novome Biotechnologies Inc
Orphomed Inc
Otsuka Pharmaceutical Co Ltd
Oxford Cannabinoid Technologies Ltd
PeptiDream Inc
Protagonist Therapeutics Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
Seed Health Inc
Serenity Bioworks Inc
Serentrix LLC
Servatus Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Sinovant Sciences HK Ltd
TenNor Therapeutics Ltd
Tryp Therapeutics Inc
University of Mississippi
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Irritable Bowel Syndrome reports